Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Sickle Cell Disease: early-phase trial registry
95 of 214 indexed Sickle Cell Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #43 of 28,707 conditions by registered trial count.
214 US clinical trials · 95 currently recruiting · #43 of 28,707 conditions by registered trial count
Sickle Cell Disease: 214 US clinical trials tracked, 95 recruiting.
Sickle Cell Disease is the subject of 214 registered US clinical trials on ClinicalTrials.gov, 95 of them currently open to new participants. 14 are in Phase 3-4 (later-stage) and 87 in Phase 1-2 (earlier-stage). The most active sponsor is St. Jude Children's Research Hospital, running 17 of these trials.
Enrollment posture brief
Registry condition sickle-cell-disease
OPEN 95 | RECR 44% | LATE 14 | EARLY 87 | RANK #43 | SPON 17
Volume-matched condition peers
Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)
Sickle Cell Disease lists 95 open slots (44% of 214 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Sickle Cell Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Sickle Cell Disease is recruiting above its size-band peers.
95 of 214 indexed trials (44.4%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Sickle Cell Disease trials is spread across many organizations.
St. Jude Children's Research Hospital accounts for 17 of 214 trials (7.9%). 101 distinct sponsors appear on at least one study for this condition label.
-
Most Sickle Cell Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 214 trials that report a genuine target (sentinel values excluded). 150 of those (70.1%) plan for fewer than 100 participants.
-
Sickle Cell Disease research is mostly interventional.
160 interventional and 54 observational studies make up this index (74.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
214 total, page 3 of 5
Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)
University of Pittsburgh
NCT04084080
Prevention of Malnutrition in Children With Sickle Cell Disease
Vanderbilt University Medical Center
NCT06397118
Epidemiology of Silent and Overt Strokes in Sickle Cell Disease
Vanderbilt University Medical Center
NCT03376893
A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)
Hoffmann-La Roche
NCT05075824
Glucose Metabolism in Sickle Cell Disease
University of Illinois at Chicago
NCT02922296
Identifying Barriers and Strategies to Support Self-efficacy for Medication Adherence With Text Messaging
Vanderbilt University
NCT02785848
The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.
Ann & Robert H Lurie Children's Hospital of Chicago
NCT04691323
Integrative Medicine in Pain Management in Sickle Cell Disease
Indiana University
NCT05045820
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
National Heart, Lung, and Blood Institute (NHLBI)
NCT03077542
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
National Heart, Lung, and Blood Institute (NHLBI)
NCT02105766
Sickle Cell Disease (SCD) Bone Pain Study
University of California, Davis
NCT05283148
Stem Cell Transplant in Sickle Cell Disease and Thalassemia
Columbia University
NCT00408447
Sickle Cell Hemoglobinopathies and Bone Health
UConn Health
NCT02306993
Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)
University of Illinois at Chicago
NCT01499888
A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)
Editas Medicine
NCT04853576
Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation
Emory University
NCT04018937
The Feasibility of the Pray Until Something Happens (PUSH) Intervention-OUTPATIENT
University of Florida
NCT06580067
Exploring Adherence Monitoring in Sickle Cell Disease
St. Jude Children's Research Hospital
NCT03708731
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease
Genetix Biotherapeutics
NCT04293185
Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease
Afimmune
NCT05861453
An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia
Imara
NCT04053803
Study on Use of Omega-3 Fatty Acids to Improve Outcomes in Individuals With Sickle Cell Disease
University of Alabama at Birmingham
NCT05758766
Sickle Cell, Pain and Mediterranean Diet
University of Illinois at Chicago
NCT06886477
iPeer2Peer Program for Youth With Sickle Cell Disease
The Hospital for Sick Children
NCT03989986
A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001)
David Williams
NCT05353647
Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease
New York Medical College
NCT01461837
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
Beam Therapeutics
NCT05456880
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat
National Heart, Lung, and Blood Institute (NHLBI)
NCT04610866
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
Vertex Pharmaceuticals Incorporated
NCT05329649
Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease
Novo Nordisk A/S
NCT05725902
Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease
City of Hope Medical Center
NCT03279094
Gene Transfer for Sickle Cell Disease
David Williams
NCT03282656
Pilot Study PBSCT with TCRab Depletion for Hemoglobinopathies
Timothy Olson
NCT04523376
Assessing Physical Function in Sickle Cell Patients Taking Voxelotor
Inova Health Care Services
NCT06023199
Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function
National Heart, Lung, and Blood Institute (NHLBI)
NCT06145282
Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease
City of Hope Medical Center
NCT03664830
Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)
Novartis Pharmaceuticals
NCT06155500
A Blood Stem Cell Transplant for Sickle Cell Disease
City of Hope Medical Center
NCT03249831
TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
City of Hope Medical Center
NCT05384756
A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients
Novartis
NCT01220115
Multi-Center Study of Iron Overload: Survey Study (MCSIO)
UCSF Benioff Children's Hospital Oakland
NCT01913548
Long Term Effects of Erythrocyte Lysis
St. Jude Children's Research Hospital
NCT00842621
The Afolabi Stroke Registry for Children and Young Adults With SCD in Northern Nigeria
Vanderbilt University Medical Center
NCT04800809
Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers
Novartis Pharmaceuticals
NCT05833022
Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease
Duke University
NCT04584528
Validating Pain Scales in Children and Young Adults
National Cancer Institute (NCI)
NCT01639950
The Brigance Assessment Of Individual Neurodevelopment In Young Children With Sickle Cell Disease- 2
St. Jude Children's Research Hospital
NCT01123863
A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Pfizer
NCT04935879
Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions
Duke University
NCT03938324
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
Reprixys Pharmaceutical Corporation
NCT01895361
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 39 |
| Phase 2 | 48 |
| Phase 3 | 11 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Sickle Cell Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Sickle Cell Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Sickle Cell Disease page
214 registered trials, 95 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 95 Sickle Cell Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- St. Jude Children's Research Hospital sponsors the most Sickle Cell Disease trials on record, review their full trial history before evaluating a specific study. See St. Jude Children's Research Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sickle Cell Disease condition card totals 214 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.